Sensibilité aux antibiotiques de souches d' Escherichia coli isolées en 1998 et 1999: résultats d'une enquête multicentrique française

Médecine et Maladies Infectieuses (Impact Factor: 0.91). 10/2000; 30(10):650-656. DOI: 10.1016/S0399-077X(00)80036-0

ABSTRACT Objective
Seven hospital lab departments were enrolled in this study in order to update and analyse data on E. coli susceptibility to antibiotics in 1998 and 1999.

Material and methods
1,114 strains were randomly selected for analysis, a large number of which had been obtained from female (65,7%) and elderly patients, and essentially from urinary samples (56%) and blood cultures (23%).

It was observed that resistance rates (R+I) were elevated for amoxicillin (44%), ticarcillin (42%), co-amoxiclav (31%) and cephalothin (36%), moderate for nalidixic acid (8%), ciprofloxacin (5%) and gentamicin (2%), and very low for ceftazidime (1%) and ceftriaxone (0.8%); 2 strains only (0.2%) were ESBL producers. Finally, it was noteworthy that pediatry units were providers of strains significantly more resistant to amoxicillin, co-amoxiclav, ticarcillin and cephalothin than strains from other units; no other risk-factor of resistance was detected. While the previous 1114 randomised strains presented MIC50 and 90 of 0.125 and 0.25 μg/mL for ceftazidime and 0,03 and 0,06 μg/mL for ceftriaxone, a complementary analysis carried out on a pool of 76 ESBL producers and 137 strains resistant (R+I) to ceftazidime and/or to cefotaxime/cetriaxone (but ESBL−) revealed that these value were increased of 7 to 9 dilutions for the 76 ESBL+ strains and of 5 to 6 for the 137 ESBL− strains in comparison with susceptible strains. Moreover these strains were observed to present elevated rates of co-resistance (R+I) to nalidixic acid, ciprofloxacin and gentamicin: 52%, 37% and 41% respectively for ESBL+ strains and 43%, 21% and 16% respectively for ESBL− strains.

  • [Show abstract] [Hide abstract]
    ABSTRACT: Objectives The increasing implication of resistant Escherichia coli in severe infections required updating of bactericidal power of β-lactams used alone or in antibiotic combinations. Methods Four clinical E. coli isolates have been selected, having different resistance mechanisms to β-lactams. Bactericidal effect of amoxicillin, piperacillin and ticarcillin have been tested by means of bactericidal kinetics, with concentrations 2 × MIC and combinations with β-lactamase inhibitors and gentamicin (at its MICs 1 or 2 mg/L). A pharmacodynamic approach used in vitro for bactericidal kinetics residual antibiotic concentrations as established previously for piperacillin, ticarcillin and their inhibitors in patients’ serum collected during treatments including these antibiotics. Results In all bactericidal tests, the addition of gentamicin to penicillins (amoxicillin, piperacillin, ticarcillin) enforced bactericidal power of penicillins. Bactericidal effects of piperacillin and ticarcillin varied when tested with or without β-lactamase inhibitors against a penicillinase producer. Against a high-level cephalosporinase producer, high amoxicillin concentration (256 mg/L) resulted in a short bactericidal effect only in the presence of gentamicin. In contrast, piperacillin presented a persistent bactericidal activity in the presence of tazobactam and gentamicin 2 mg/L, but regrowth occurred with gentamicin 1 mg/L. Ticarcillin showed the most rapid and persistent (> 24 h) bactericidal effect when associated with clavulanic acid and gentamicin 2 mg/L. The tests carried out in simulation of in vivo conditions provided similar bactericidal effects as in vitro. Synergistic effects of combination of a β-lactam plus gentamicin is confirmed all along the study.
    Antibiotiques 02/2008; 10(1):50-58.
  • [Show abstract] [Hide abstract]
    ABSTRACT: Objective The authors had for aim to evaluate the frequency of isolation and the antibiotic susceptibility of bacteria responsible for urinary infections among in and out-patients.
    Médecine et Maladies Infectieuses 06/2008; 38(6):324-327. · 0.91 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Objectives – To determine the incidence of colonisation/infection with E. coli in the hospitals of Franche-Comté in 1999, to update the data concerning its sensitivity to antibiotics and its genomic diversity.Design – One hundred and ninety nine clinical strains isolated in november 1999 were characterized by antibiotic susceptibility and PFGE. We compared disc diffusion and E-test to establish the frequency of resistance to β-lactams.Results – The incidences of colonised/infected patients were 4.63 per 100 admissions and 7.21 per 1000 patient days. The weekly rate of colonisation/infection per 100 beds was ranging from 3.3 to 11.5% according to the speciality. Strains had been obtained essentially from urinary samples (64.5%). It was observed that β-lactams resistance rates (R + I) were respectively 36.7% for amoxycillin, 27.1% for co-amoxyclav, 35.7% for ticarcillin and 2.5% for ceftazidime. MIC determination for co-amoxyclav using E-test showed that the rate of resistance (MIC > 16 mg/L) was 5%. Moreover MIC values of resistant strains were moderate (24 to 48 mg/L). The dendrogram constructed according to the percent similarity of DNA restriction profile showed a great genomic diversity among E. coli strains.Conclusion – Penicillinase production is the most frequent mechanism of resistance to amoxycillin among E.coli isolates. Resistance to co-amoxyclav should have only a limited therapeutic impact. Indeed, the majority of the strains with decreased susceptibility are classified as intermediate and the resistant strains present MIC values relatively low. The genomic diversity confirms that the diffusion of β-lactams resistance in E. coli is not related to clonal dissemination.
    Médecine et Maladies Infectieuses 01/2002; 32(1):8-18. · 0.91 Impact Factor